Search research articles
Contact Us
Filters
Showing results (231-240 of 304) with videos related to
Page
of 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers
Julia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD
Zofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R Hui, E B Garon, J W Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors
Adil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 10, 2021
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
Nanruoyi Zhou, Maria A Velez, Benjamin Bachrach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
Clinical Lung Cancer
|
August 31, 2025
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Niels Reinmuth, Jonathan W Goldman, Yuanbin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2019
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James C H Yang, Sang-We Kim, Dong-Wan Kim, et al.
Page
of 31
Search research articles
Search
Showing results (231-240 of 304) with videos related to
Sort By:
Page
of 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers
Julia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD
Zofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R Hui, E B Garon, J W Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors
Adil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 10, 2021
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
Nanruoyi Zhou, Maria A Velez, Benjamin Bachrach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
Clinical Lung Cancer
|
August 31, 2025
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Niels Reinmuth, Jonathan W Goldman, Yuanbin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2019
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James C H Yang, Sang-We Kim, Dong-Wan Kim, et al.
Page
of 31